Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $84.8 Million - $107 Million
400,000 New
400,000 $86.3 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $14.6 Million - $20.1 Million
75,000 Added 60.0%
200,000 $53.4 Million
Q2 2022

Aug 15, 2022

BUY
$187.54 - $223.02 $23.4 Million - $27.9 Million
125,000 New
125,000 $25.5 Million
Q1 2022

May 16, 2022

SELL
$193.77 - $244.14 $48.4 Million - $61 Million
-250,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $39.2 Million - $50.4 Million
175,000 Added 233.33%
250,000 $60 Million
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $21.2 Million - $27.7 Million
75,000 New
75,000 $21.2 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $48.6 Million - $56.9 Million
-200,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $47.3 Million - $71.1 Million
200,000 New
200,000 $49 Million
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $51.7 Million - $68.5 Million
-200,000 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $40.3 Million - $51.2 Million
-150,000 Reduced 42.86%
200,000 $63.3 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $76.1 Million - $85.4 Million
350,000 New
350,000 $81.5 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $87.7 Million - $96.7 Million
-400,000 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $32.5 Million - $50.8 Million
150,000 Added 60.0%
400,000 $94.6 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $13.9 Million - $17.6 Million
-50,000 Reduced 16.67%
250,000 $75.2 Million
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $44 Million - $57.6 Million
-150,000 Reduced 33.33%
300,000 $106 Million
Q2 2018

Aug 14, 2018

SELL
$257.52 - $306.91 $16.7 Million - $19.9 Million
-65,000 Reduced 12.62%
450,000 $131 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $134 Million - $189 Million
515,000 New
515,000 $141 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Camber Capital Management LP Portfolio

Follow Camber Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Camber Capital Management LP with notifications on news.